Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions

Yiqing Zhang, Xiaoxia Liu, D. Klionsky, B. Lu, Q. Zhong
{"title":"Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions","authors":"Yiqing Zhang, Xiaoxia Liu, D. Klionsky, B. Lu, Q. Zhong","doi":"10.1093/lifemedi/lnac043","DOIUrl":null,"url":null,"abstract":"\n Targeted degradation, having emerged as a powerful and promising strategy in drug discovery in the past two decades, has provided a solution for many once undruggable targets involved in various diseases. While earlier targeted degradation tools, as exemplified by PROteolysis-TArgeting Chimera (PROTAC), focused on harnessing the ubiquitin-proteasome system, novel approaches that aim to utilize autophagy, a potent, lysosome-dependent degradation pathway, have also surfaced recently as promising modalities. In this Review, we first introduce the mechanisms that establish selectivity in autophagy, which provides the rationales for autophagy-based targeted degradation; we also provide an overview on the panoply of cellular machinery involved in this process, an arsenal that could be potentially harnessed. On this basis, we propose four strategies for designing autophagy-based targeted degraders, including Tagging Targets, Directly Engaging Targets, Initiating Autophagy at Targets, and Phagophore-Tethering to Targets. We introduce the current frontiers in this field, including AUtophagy-TArgeting Chimera (AUTAC), Targeted Protein Autophagy (TPA), AUTOphagy-TArgeting Chimera (AUTOTAC, not to be confused with AUTAC), AuTophagosome TEthering Compound (ATTEC), and other experimental approaches as case studies for each strategy. Finally, we put forward a workflow for generating autophagy-based degraders and some important questions that may guide and inspire the process.","PeriodicalId":74073,"journal":{"name":"Life medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/lifemedi/lnac043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Targeted degradation, having emerged as a powerful and promising strategy in drug discovery in the past two decades, has provided a solution for many once undruggable targets involved in various diseases. While earlier targeted degradation tools, as exemplified by PROteolysis-TArgeting Chimera (PROTAC), focused on harnessing the ubiquitin-proteasome system, novel approaches that aim to utilize autophagy, a potent, lysosome-dependent degradation pathway, have also surfaced recently as promising modalities. In this Review, we first introduce the mechanisms that establish selectivity in autophagy, which provides the rationales for autophagy-based targeted degradation; we also provide an overview on the panoply of cellular machinery involved in this process, an arsenal that could be potentially harnessed. On this basis, we propose four strategies for designing autophagy-based targeted degraders, including Tagging Targets, Directly Engaging Targets, Initiating Autophagy at Targets, and Phagophore-Tethering to Targets. We introduce the current frontiers in this field, including AUtophagy-TArgeting Chimera (AUTAC), Targeted Protein Autophagy (TPA), AUTOphagy-TArgeting Chimera (AUTOTAC, not to be confused with AUTAC), AuTophagosome TEthering Compound (ATTEC), and other experimental approaches as case studies for each strategy. Finally, we put forward a workflow for generating autophagy-based degraders and some important questions that may guide and inspire the process.
操纵人类疾病中的自噬降解:从机制到干预
在过去二十年中,靶向降解作为一种强有力和有前途的药物发现策略出现,为涉及各种疾病的许多曾经无法治疗的目标提供了解决方案。虽然早期的靶向降解工具,如PROteolysis-TArgeting Chimera (PROTAC),专注于利用泛素-蛋白酶体系统,但旨在利用自噬(一种有效的,依赖于溶酶体的降解途径)的新方法最近也作为有希望的方式出现。在这篇综述中,我们首先介绍了自噬中建立选择性的机制,这为基于自噬的靶向降解提供了依据;我们还概述了在这一过程中涉及的细胞机制,这是一个可能被利用的武器库。在此基础上,我们提出了四种设计基于自噬的靶向降解物的策略,包括标记靶标、直接参与靶标、在靶标处启动自噬和噬菌体与靶标的连接。我们介绍了目前该领域的前沿研究,包括自噬靶向嵌合体(AUTAC)、靶向蛋白自噬(TPA)、自噬靶向嵌合体(AUTOTAC,不要与AUTAC混淆)、自噬体系固化合物(ATTEC)以及其他实验方法,作为每种策略的案例研究。最后,我们提出了生成基于自噬的降解物的工作流程和一些可能指导和启发这一过程的重要问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信